Celecoxib potently inhibits TNFα-induced nuclear translocation and activation of NF-κB

Biochemical Pharmacology

Volumn 76, Issue 5, 2008, Pages 662-671

  Funakoshi Tago, Megumi ^a   Shimizu, Taeko ^a   Tago, Kenji ^b   Nakamura, Motohiro ^b   Itoh, Hiroshi ^b   Sonoda, Yoshiko ^a   Kasahara, Tadashi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Graduate School of Biological Sciences   (Japan)

Author keywords

CCL2 MCP 1; Celecoxib; CXCL1 KC; NF B; TNF

Indexed keywords

CELECOXIB; CXCL1 CHEMOKINE; CYTOKINE; I KAPPA B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DRUG POTENCY; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; CELL NUCLEUS; CYCLOOXYGENASE 2 INHIBITORS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; MICE; NF-KAPPA B; NIH 3T3 CELLS; POLYMERASE CHAIN REACTION; PROTEIN TRANSPORT; PYRAZOLES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49149090886     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.06.015     Document Type: Article

References (49)

1. Piper P.J., and Vane J.R. Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 223 (1969) 29-35
2. Smith W.L., Meade E.A., and DeWitt D.L. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann NY Acad Sci 714 (1994) 136-142
3. O'Banion M.K., Winn V.D., and Young D.A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89 (1992) 4888-4892
4. O'Neill G.P., and Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330 2 (1993) 156-160
5. McGettigan P., and Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des 6 (2000) 1693-1724
6. DeWitt D.L. COX-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55 (1999) 625-631
7. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, Celecoxib). J Med Chem 40 (1997) 1347-1365
8. Lipsky P.E., and Isakson P.C. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol Suppl 49 (1997) 9-14
9. Frampton J.E., and Keating G.M. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs 67 (2007) 2433-2472
10. Shi S., and Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64 (2008) 233-252
11. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
12. Firestein G.S., Alvaro-Gracia J.M., and Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144 (1990) 3347-3353
13. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322 6079 (1986) 547-549
14. Williams R.O., Mason L.J., Feldmann M., and Maini R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91 7 (1994) 2762-2766
15. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 19 (2001) 163-196
16. Kunsch C., and Rosen C.A. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 13 10 (1993) 6137-6146
17. Ping D., Jones P.L., and Boss J.M. TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the MCP-1/JE gene. Immunity 4 5 (1996) 455-469
18. Shimizu H., Mitomo K., Watanabe T., Okamoto S., and Yamamoto K. Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 10 2 (1990) 561-568
19. Rothe M., Wong S.C., Henzel W.J., and Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78 4 (1994) 681-692
20. Hsu H., Huang J., Shu H.B., Baichwal V., and Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 4 (1996) 387-396
21. Takeuchi M., Rothe M., and Goeddel D.V. Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 271 33 (1996) 19935-19942
22. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., and Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388 6642 (1997) 548-554
23. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., and Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91 2 (1997) 243-252
24. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278 5339 (1997) 860-866
25. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93 June (7) (1998) 1231-1240
26. Funakoshi-Tago M., Sonoda Y., Tanaka S., Hashimoto K., Tago K., Tominagax S., et al. Tumor necrosis factor-induced nuclear factor kappaB activation is impaired in focal adhesion kinase-deficient fibroblasts. J Biol Chem 278 31 (2003) 29359-29365
27. Pallard C., Gouilleux F., Bénit L., Cocault L., Souyri M., Levy D., et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J 14 12 (1995) 2847-2856
28. Cao Z., Xiong J., Takeuchi M., Kurama T., and Goeddel D.V. TRAF6 is a signal transducer for interleukin-1. Nature 383 6599 (1996) 443-446
29. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 277 27 (2002) 24625-24630
30. Vietor I., Schwenger P., Li W., Schlessinger J., and Vilcek J. Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J Biol Chem 268 25 (1993) 18994-18999
31. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 6748 (1999) 82-85
32. Beyaert R., Cuenda A., Vanden Berghe W., Plaisance S., Lee J.C., Haegeman G., et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 15 8 (1996) 1914-1923
33. Shishodia S., Koul D., and Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor Celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173 3 (2004) 2011-2022
34. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58 3 (1998) 409-412
35. Grösch S., Tegeder I., Niederberger E., Bräutigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor Celecoxib. FASEB J 15 14 (2001) 2742-2744
36. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor Celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 15 (2000) 11397-11403
37. Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., and DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60 21 (2000) 6045-6051
38. Fagerlund R., Kinnunen L., Köhler M., Julkunen I., and Melén K. NF-κB is transported into the nucleus by importin α3 and importin α4. J Biol Chem 280 16 (2005) 15942-15951
39. Waldmann I., Wälde S., and Kehlenbach R.H. Nuclear import of c-jun is mediated by multiple transport receptors. J Biol Chem 282 38 (2007) 27685-27692
40. Zhong H., SuYang H., Erdjument-Bromage H., Tempst P., and Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89 3 (1997) 413-424
41. Zhong H., Voll R.E., and Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1 5 (1998) 661-671
42. Sakurai H., Suzuki S., Kawasaki N., Nakano H., Okazaki T., Chino A., Doi T., and Saiki I. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278 38 (2003) 36916-36923
43. Hu J., Nakano H., Sakurai H., and Colburn N.H. Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Arcinogenesis 25 10 (2004) 1991-2003
44. Callejas N.A., Fernández-Martínez A., Castrillo A., Boscá L., and Martín-Sanz P. Selective inhibitors of cyclooxygenase-2 delay the activation of nuclear factor kappa B and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide. Mol Pharmacol 63 3 (2003) 671-677
45. Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 15 17 (1996) 4682-4690
46. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65 15 (2005) 6934-6942
47. Boehm J.S., Zhao J.J., Yao J., Kim S.Y., Firestein R., Dunn I.F., et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129 6 (2007) 1065-1079
48. Kalvakolanu D.V., and Sen G.C. Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NF-kappa B in mouse embryonal carcinoma cells. Proc Natl Acad Sci USA 90 8 (1993) 3167-3171
49. Arlt A., Gehrz A., Müerköster S., Vorndamm J., Kruse M.L., Fölsch U.R., et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22 21 (2003) 3243-3251